Dispensing and administration of emergency opioid antagonist without a

Similar documents
SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

SECTION PRESCRIPTIONS

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

Naloxone Access Statutes

H 7816 S T A T E O F R H O D E I S L A N D

10/20/14& the administration of nasal naloxone by school nurses. for nasal naloxone

RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS

ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque, NM. [ NMAC - N, ; A, ]

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

Sub. S.B. 119 As Passed by the Senate

R ADMINISTERING AN OPIOID ANTIDOTE. B. Acquisition, Maintenance, Accessibility, and Documentation of an Opioid Antidote

Naloxone Access Statutes

WHAT YOU NEED TO KNOW TO ABOUT AB 474

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

Be it enacted by the People of the State of Illinois,

Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions

Lobbyist-in-a-Box: (VPhAT) created on 01/15 at 10:11

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2017 GENERAL SESSION

SENATE FILE NO. SF0042. Sponsored by: Joint Judiciary Interim Committee A BILL. for. AN ACT relating to public health and safety; creating the

PROPOSED AMENDMENTS TO HOUSE BILL 3440

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT

Naloxone Standardized Procedures Illinois Departments of DFPR, DPH & DHS Opioid Antagonist Initiative

History Note: Authority G.S ; ; ; Eff. May 1, 1997; Amended Eff. January 1, 2015; March 1, 2013.

247 CMR BOARD OF REGISTRATION IN PHARMACY

A Bill Regular Session, 2015 SENATE BILL 717

CRITICAL POLICY REFERENCE MANUAL FILE CODE: X Monitored X Mandated Sample Policy X Other Reasons

STATUTORY INSTRUMENTS. S.I. No. 488 of 2008 REGULATION OF RETAIL PHARMACY BUSINESSES REGULATIONS 2008

Unofficial translation /Ministry of Social Affairs and Health. No. 548/2008. Government Decree on Narcotics Control

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

ARKANSAS DEPARTMENT OF HEALTH

ISSUING AGENCY: Regulation and Licensing Department - NM Board of Osteopathic Medical Examiners.

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26)

Protocol For: Personally Furnishing Naloxone. Update Log

ADMINISTRATION OF NALOXONE HCI REVISED: 10/17

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation.

Illinois Heroin Crisis Act and Family Physicians. October 14, 2015 Hinsdale Family Medicine Residency Faculty Development Program

Thailand s experience in developing the Reclassification guideline

January 2017 FEDERAL LAW CURRENT BOARD MEMBERS. June 24, Ben Kesner RPh Executive Director Shelley Bagwell RPh PMP Director.

Referred to Committee on Health and Human Services. SUMMARY Establishes an opioid overdose prevention policy for Nevada.

Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:

UTAH S CONTROLLED SUBSTANCE DATABASE PROGRAM (CSDB)

2016 Jurisprudence Update. (Phone) (Fax)

Guideline for the Rational Use of Controlled Drugs

Temple University Beasley School of Law. Project on Harm Reduction in the Health Care System

Supplement No. 1 published with Extraordinary Gazette No. 65 dated 19 th August, 2016.

MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent

Request for Proposal. PA ACT 139 Naloxone Purchase

CSS Perspective - Opioid Risk Management

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program

BOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director

PART 1306 PRESCRIPTIONS. 21 CFR Ch. II ( Edition)

CHAPTER NINE INSULIN AND GLUCAGON ADMINISTRATION

This Chapter Contains:

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

PLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.

DIVISION CIRCULAR #21 (N/A) DEPARTMENT OF HUMAN SERVICES DIVISION OF DEVELOPMENTAL DISABILITIES

Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions

Good Samaritan and Naloxone Bill Status Report Carryover 2016 and Special Sessions

Destruction of Narcotics, Controlled Drugs and other Targeted Substances

Missouri Guidelines for the Use of Controlled Substances for the Treatment of Pain

TEXAS COMPASSIONATE-USE ACT

FEDERAL LAW CURRENT BOARD MEMBERS. January 28, Drug Disposal. Ben Kesner Executive Director Cheranne McCracken State Drug Inspector

3 By Representatives Sells, Weaver, Harper, South, McCutcheon, 4 Harbison, Butler, Mooney, Hanes, Williams (JW), Wilcox, Scott,

Michigan Opioid Legislation Hospital Compliance Checklist

Guidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception

AN ACT IN THE COUNCIL OF THE DISTRICT OF COLUMBIA

HEB Pharmacy Conference October 25, 2014

Objectives 1/25/18. An Update on Controlled Substance Prescribing Laws & Rules for CNMs. Exclusionary Formulary Effective: May 17, 2017

1 HB By Representative Williams (JD) 4 RFD: Health. 5 First Read: 09-JAN-18 6 PFD: 11/28/2017. Page 0

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998

Rule Governing the Prescribing of Opioids for Pain

Public Health Impacts of 2016 West Virginia Legislation

As Passed by the House. Regular Session Sub. H. B. No

Template Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices

North Dakota Board of Pharmacy

SOUTH DAKOTA BOARD OF REGENTS. Policy Manual

79th OREGON LEGISLATIVE ASSEMBLY Regular Session. Enrolled. House Bill 3440

CLINTON-ESSEX-WARREN-WASHINGTON BOCES Drug and Alcohol Testing. Champlain Valley Educational Services P.O. Box 455 Plattsburgh, NY

Report to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program

Opioid Management of Chronic (Non- Cancer) Pain

Prepublication Requirements

The Changing Landscape of Opioids & Workers Compensation. Presented by: David Campbell, MA, CRC State of Michigan Workers Compensation Agency

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients

Pursuant to the authority vested in the Commissioner of Health by section 3369-a of the Public

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW HOUSE BILL 243

SUBJECT: Effective Date: Policy Number: Controlled Substance and Prescription Drugs 11/30/

Vermont. Prescribing and Dispensing Profile. Research current through November 2015.

PREREQUISITES: VETA 1104, VETA 1201 and MATH This class must be taken before or in conjunction with VETT 2100.

MARYLAND BOARD OF PHARMACY

Readopt with amendment Med 502, effective (Document #11090), to read as follows:

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.

Legal Considerations for. Immunizations

CANNABIS MANAGEMENT CORPORATION REGULATIONS

Administration of Medication

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.

Transcription:

68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies needed to administer an emergency opioid antagonist to a patient, bystander, first responder agency or school nurse without a prescription in accordance with written protocol approved by the board. (b) Any pharmacist dispensing an emergency opioid antagonist pursuant to this regulation must maintain a current, signed copy of the written protocol approved by the board. (c) The board-established protocol for the dispensing of an emergency opioid antagonist by a pharmacist shall include, but is not limited to, the following: (1) A description of the clinical pharmacology of emergency opioid antagonists; (2) Indications for use of emergency opioid antagonists as rescue therapy, including criteria for identifying persons eligible to receive an emergency opioid antagonist under the protocol; (3) Precautions and contraindications concerning dispensing an emergency opioid antagonist; (4) Assessment and follow-up actions by the pharmacist; (5) Procedures for documenting dispensation of an emergency opioid antagonist; and (6) Any emergency opioid antagonists authorized to be dispensed, including the following information: (A) Name of product; (B) Dose; (C) Route of administration and required delivery device; and

Page 2 (D) Directions for use. (d) Any pharmacist who dispenses an emergency opioid antagonist pursuant to this regulation shall instruct the individual to whom an emergency opioid antagonist is dispensed to summon emergency medical services as soon as practicable either before or after administering the emergency opioid antagonist. (e) Each pharmacist dispensing an emergency opioid antagonist pursuant to this regulation shall provide in-person counseling, training and written educational materials to the individual to whom the emergency opioid antagonist is dispensed, appropriate to the dosage form dispensed, including the following: (1) Risk factors of opioid overdose; (2) Strategies to prevent opioid overdose; (3) Signs of opioid overdose; (4) Steps in responding to an overdose; (5) Information on emergency opioid antagonists; (6) Procedures for administering an emergency opioid antagonist; (7) Proper storage, disposal and expiration of the emergency opioid antagonist dispensed; (8) Information on where to obtain a referral for substance use disorder treatment; and (9) For any first responder agency or school nurse, the requirements to keep inventory records and report any administration of the emergency opioid antagonist to the appropriate healthcare provider pursuant to this regulation. (f) If a patient or bystander refuses counseling, the pharmacist shall not dispense the emergency opioid antagonist.

Page 3 (g) Each pharmacist dispensing an emergency opioid antagonist to a first responder agency or school nurse pursuant to this regulation shall ensure that such first responder agency or school nurse is provided with written education and training materials that meet the requirements listed in paragraphs (d) and (e). (h) Each emergency opioid antagonist dispensed by a pharmacist shall be labeled in accordance with the pharmacy practice act and any rules and regulations promulgated thereunder. (i) Each pharmacist shall document the dispensation of any emergency opioid antagonist pursuant to this regulation in a written or electronic prescription record for the individual or first responder agency to whom the emergency opioid antagonist is dispensed. The pharmacist shall record themselves or the protocol healthcare practitioner as the prescriber. The prescription record shall be maintained such that the required information is readily retrievable during the pharmacy s normal operating hours, and shall be securely stored within the pharmacy for a period of five years. (j) Any of the following individuals or facilities licensed or registered with the board of pharmacy or the board of healing arts may make sales of emergency opioid antagonists at wholesale to a first responder agency or school nurse: (A) A pharmacist; (B) a physician medical director; or (C) a pharmacy.

Page 4 (k) All board-established protocols shall be signed and dated by the physician and the pharmacist prior to implementation, and shall be maintained by the pharmacist. The protocol shall be made readily available to the pharmacist-in-charge, the board, and the board s designee. (l) Each pharmacist that dispenses emergency opioid antagonists pursuant to this regulation, shall notify the board, in a manner prescribed by the board, within five days of establishing an approved protocol. Any pharmacist that no longer dispenses emergency opioid antagonists pursuant to the protocol shall notify the board, in a manner prescribed by the board, within thirty days of discontinuation. (m) Each first responder, scientist and technician operating under a first responder agency administering an emergency opioid antagonist shall: (1) Summon emergency medical services as soon as practicable either before or after administering the emergency opioid antagonist; (2) immediately provide information related to the administration to any responding emergency medical services personnel, any emergency room personnel, or any treating physician; and (3) notify the physician medical director for the first responder agency within 24 hours of administration. (n) Each first responder agency that is dispensed an emergency opioid antagonist shall ensure that any first responder, scientist or technician operating under such first responder agency is appropriately trained on the use of emergency opioid antagonists, and can meet the training requirements listed in paragraphs (d) and (e), and the board-established protocol.

Page 5 (Authorized by 2017 HB 2217, sec. 1; implementing 2017 HB 2217, sec. 1; effective April 16, 2004; amended April 18, 2008; effective T-.)